ANGO Angiodynamics Inc - 8-K

Item 8.01 Other Events

On April 23, 2026, AngioDynamics, Inc. (the “Company” or “AngioDynamics”) filed a complaint commencing a patent infringement lawsuit in the United States District Court
for the District of Delaware against Endovascular
Engineering, Inc. (“E2”).

The complaint alleges that E2’s Hēlo Thrombectomy System unlawfully incorporates several features protected

by registered patents held by the Company, including relating to the Company’s proprietary self-expanding funnel technology and related features that improve the removal of thrombi and emboli from the body. The complaint seeks damages and equitable
relief. The Company believes that vigorous protection of its intellectual property rights supports continued innovation and improved care for patients.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the
Company’s intention to enforce its intellectual property rights. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of management for future operations, outcomes of litigation, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,”
“believes,” “seeks,” “estimates,” “projects”, “optimistic,” or variations of such words and similar expressions, are forward-looking statements. Investors are cautioned that actual events or results may differ materially from AngioDynamics’
expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the outcome of the litigation against E2, AngioDynamics’ ability to successfully enforce its intellectual property
rights and to defend its patents, the costs associated with the E2 lawsuit,  as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31,
2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.